This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Skip to main content
null
Gonzaga Law Review
  • Menu
  • Articles
    • General
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • search
  • Facebook (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:34495/feed
ISSN 0046-6115
General
Vol. 52, Issue 3, 2017January 01, 2017 PDT

MYLAN’S PRICE HIKE OF EPIPENS: HOLDING THE PHARMACEUTICAL GIANT ACCOUNTABLE

Hannah Hadland,
consumer lawprescriptionsantitrust
Photo by Hyttalo Souza on Unsplash
Gonzaga Law Review
Hannah Hadland, MYLAN’S PRICE HIKE OF EPIPENS: HOLDING THE PHARMACEUTICAL GIANT ACCOUNTABLE, 52 Gonzaga Law Review 587 (2017).

View more stats

Powered by Scholastica, the modern academic journal management system